Q: Are you developing the oral semaglutide individually or as a validation tool for other incretins, and how does this align with your capital constraints? A: Our primary focus is on RT-114 due to capital constraints. The semaglutide program, RT-116, is a discovery program used to validate delivery of incretins, showing 107% bioavailability. We are